TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7878168

Group type: EXPERIMENTAL
Intervention: Diazepam (0.1 mg/kg body weight i.v.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Phobic stimulation
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Neutral stimulation
Number of subjects: 8
Study: 2094946

Group type: EXPERIMENTAL
Intervention: Controlled-release salbutamol (Group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Salbutamol (Group A)
Number of subjects: 20
Study: 367406

Group type: EXPERIMENTAL
Intervention: Phenytoin treatment (aimed at maintaining plasma phenytoin levels between 40 and 80 mumol/litre)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no phenytoin treatment)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Phenytoin treatment
Number of subjects: 150
Study: 31995556

Group type: COMPARATOR
Intervention: E/C/F/TAF
Number of subjects: 150

Group type: COMPARATOR
Intervention: R/F/TAF
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: LDV/SOF
Number of subjects: 150
Study: 30855502

Group type: EXPERIMENTAL
Intervention: Cannulated pedicle screws
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional pedicle screws
Number of subjects: 28
Study: 27870553

Group type: EXPERIMENTAL
Intervention: NIO® (New Intraosseous Persys Medical)
Number of subjects: 50

Group type: COMPARATOR
Intervention: EZ‐IO® (Teleflex Medical)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: NIO® and EZ‐IO®
Number of subjects: 50

Group type: COMPARATOR
Intervention: EZ‐IO®
Number of subjects: 50
Study: 26185394

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 87

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 87
Study: 24240641

Group type: EXPERIMENTAL
Intervention: Silicone tape
Number of subjects: 24

Group type: COMPARATOR
Intervention: Paper tape
Number of subjects: 24
Study: 22564709

Group type: EXPERIMENTAL
Intervention: Lixisenatide (20 µg once daily)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study: 19897413

Group type: EXPERIMENTAL
Intervention: 9g Sodium Oxybate (SXB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 9g Sodium Oxybate (SXB) + 200mg Modafinil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10mg Zolpidem
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 60
Study: 17673575

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 15588905

Group type: EXPERIMENTAL
Intervention: Transdermal iontophoretic delivery of R‐apomorphine with surfactant formulation pretreatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Transdermal iontophoretic delivery of R‐apomorphine without surfactant formulation (control)
Number of subjects: 16
Study: 12122510

Group type: EXPERIMENTAL
Intervention: Intravenous liposomal amphotericin B + oral itraconazole
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Intravenous fluconazole + oral itraconazole
Number of subjects: 129

Group type: COMPARATOR
Intervention: Intravenous and oral placebo
Number of subjects: 129
Study: 10619648

Group type: EXPERIMENTAL
Intervention: S1 ERPs (go and no-go)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S1 ERPs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S2 ERPs
Number of subjects: 0
Study: 8537671

Group type: EXPERIMENTAL
Intervention: 7‐valent pneumococcal conjugate vaccine (7‐OMPC) followed by one dose of 23‐valent polysaccharide pneumococcal vaccine (23‐PS)
Number of subjects: 39

Group type: COMPARATOR
Intervention: 23‐valent polysaccharide pneumococcal vaccine (23‐PS) only
Number of subjects: 39
Study: 1864539

Group type: EXPERIMENTAL
Intervention: Oral eudragit S coated 5 amino salicylic acid (n = 12)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Rectal prednisolone enemas (n = 15)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 33
Study: 6357175

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole injection and placebo suppository
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Metronidazole suppository and cotrimoxazole injection
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Metronidazole suppository and placebo injection
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo suppository and placebo injection
Number of subjects: 283
Study: 31575699

Group type: EXPERIMENTAL
Intervention: Eculizumab prophylaxis
Number of subjects: 397

Group type: COMPARATOR
Intervention: No eculizumab prophylaxis
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Eculizumab use
Number of subjects: 397
Study: 28028076

Group type: EXPERIMENTAL
Intervention: Inorganic nitrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0
Study: 25937539

Group type: EXPERIMENTAL
Intervention: Prostatic urethral lift (PUL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 80
Study: 23222095

Group type: EXPERIMENTAL
Intervention: Buprenorphine taper (7 vs 28 days)
Number of subjects: 516
Study: 21272849

Group type: EXPERIMENTAL
Intervention: Foley catheter left in place for a maximum of 24 hours
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Foley catheter left in place for a maximum of 12 hours
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Prostaglandin E(2) controlled-release vaginal insert
Number of subjects: 397
Study: 19304880

Group type: EXPERIMENTAL
Intervention: Granisetron transdermal patch (52 cm²)
Number of subjects: 793

Group type: COMPARATOR
Intervention: Oral granisetron (2 mg)
Number of subjects: 793
Study: 16730534

Group type: EXPERIMENTAL
Intervention: Intratympanic steroid treatment (0.5 mL of methylprednisolone acetate, 80 mg/2 mL, administered 4 times over 15 days)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no intratympanic treatment)
Number of subjects: 37
Study: 15583586

Group type: EXPERIMENTAL
Intervention: Tretinoin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12577354

Group type: EXPERIMENTAL
Intervention: Zhuhuang Granule No. 2 (ZHG2)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Composite indigo capsule (control)
Number of subjects: 67
Study: 1426320

Group type: EXPERIMENTAL
Intervention: GnRH-a initiation on cycle day 21 before COH (group I)
Number of subjects: 55

Group type: COMPARATOR
Intervention: GnRH-a initiation concurrently with COH on cycle day 3 (group II)
Number of subjects: 55

Group type: COMPARATOR
Intervention: GnRH-a initiation concurrently with COH (group II)
Number of subjects: 55
Study: 6320627

Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose gum
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Locust bean gum
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Karaya gum
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cellulose
Number of subjects: 12

Group type: COMPARATOR
Intervention: Basal diet
Number of subjects: 12
Study: 29869538

Group type: EXPERIMENTAL
Intervention: Topical Coqun (100 mg CQ10, 500 mg Vitamin E TPGS) twice daily for 1 month preoperatively
Number of subjects: 64

Group type: COMPARATOR
Intervention: No treatment (pseudo-exfoliative glaucoma group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Pseudo-exfoliation syndrome (control group)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: All groups (including malondialdehyde levels)
Number of subjects: 64
Study: 29971527

Group type: EXPERIMENTAL
Intervention: 10 mg dapagliflozin (n=21)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 4 g OM‐3CA (n=20)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Combination of dapagliflozin and OM‐3CA (n=22)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (n=21)
Number of subjects: 84
Study: 27787386

Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy (GCBT)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Interactive Lectures (IL)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study: 25218552

Group type: EXPERIMENTAL
Intervention: 7 mg nicotine patch
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 78
Study: 22433020

Group type: EXPERIMENTAL
Intervention: Clarithromycin (15 mg/kg for 3 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (regular GINA-guided exacerbation treatment)
Number of subjects: 40
Study: 20457725

Group type: EXPERIMENTAL
Intervention: Binaural broadband hearing instruments
Number of subjects: 36

Group type: COMPARATOR
Intervention: Advanced digital hearing instruments
Number of subjects: 36

Group type: COMPARATOR
Intervention: Unaided
Number of subjects: 36
Study: 18506618

Group type: EXPERIMENTAL
Intervention: Integrated Assertive Community Treatment (IACT)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment Only (ACTO)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: ACTO vs IACT
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Treatment by time interactions
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Mediation effects
Number of subjects: 191
Study: 16186474

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 116

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 116
Study: 12963672

Group type: EXPERIMENTAL
Intervention: Family-focused therapy (FFT) with pharmacotherapy
Number of subjects: 101

Group type: COMPARATOR
Intervention: Crisis management (CM) with pharmacotherapy
Number of subjects: 101
Study: 11054613

Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 0
Study: 8695248

Group type: COMPARATOR
Intervention: Ondansetron (OND) 8 mg x 3 i.v. on day 1 and 8 mg x 2 orally on day 2
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Granisetron (GRA) 3 mg i.v. on day 1
Number of subjects: 124

Group type: COMPARATOR
Intervention: Ondansetron (OND)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Granisetron (GRA)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Preference for Ondansetron (OND)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Preference for Granisetron (GRA)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 124
Study: 1809589

Group type: EXPERIMENTAL
Intervention: Augmented betamethasone dipropionate (ABD) ointment 0.05% applied in an intermittent pulse dose regimen (three consecutive applications 12 h apart, once a week for a maximum treatment period of 6 months)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 90
Study: 3891159

Group type: EXPERIMENTAL
Intervention: Ego boosting during hypnosis
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Induction of a hypnotic state
Number of subjects: 14

Group type: COMPARATOR
Intervention: Trance state induction (Control)
Number of subjects: 14
Study: 30464392

Group type: EXPERIMENTAL
Intervention: Fimasartan/Rosuvastatin fixed-dose combination (120 mg fimasartan and 20 mg rosuvastatin)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Separate co-administration of fimasartan and rosuvastatin
Number of subjects: 78
Study: 26708006

Group type: EXPERIMENTAL
Intervention: Diet Modification intervention (DM‐I)
Number of subjects: 48835
Study: 24872557

Group type: EXPERIMENTAL
Intervention: Activities in the posterior portion of the dorsal medial prefrontal cortex (DmPFC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activities in the anterior DmPFC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brain signal change in the ventral mPFC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dorsal anterior cingulate cortex activity
Number of subjects: 0
Study: 22264499

Group type: EXPERIMENTAL
Intervention: 5 g XOS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: INU‐XOS (3 g inulin + 1 g XOS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wheat maltodextrin (placebo)
Number of subjects: 60
Study: 21457067

Group type: EXPERIMENTAL
Intervention: Matsuda insulin sensitivity index (MISI)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: LMTT disposition index (LMTT-DI)
Number of subjects: 24
Study: 18095238

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day) + Metformin (2 g/day)
Number of subjects: 596

Group type: COMPARATOR
Intervention: Sulphonylurea (Glibenclamide 5 mg/day or Gliclazide 80 mg/day) + Metformin (2 g/day)
Number of subjects: 596
Study: 16931991

Group type: EXPERIMENTAL
Intervention: Basal-bolus ropivacaine
Number of subjects: 83

Group type: COMPARATOR
Intervention: Patient-controlled intravenous morphine
Number of subjects: 83
Study: 13678101

Group type: EXPERIMENTAL
Intervention: Starting with the mandibular impression (easier)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Starting with the maxillary impression (harder)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Younger children (5 to 6 years)
Number of subjects: 48
Study: 10891025

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (information about techniques to help infants at immunization)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 102
Study: 8832493

Group type: EXPERIMENTAL
Intervention: MDI A (HFA-134a inhalation aerosol system), 4 inhalations four times per day for 14 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: MDI A (HFA-134a inhalation aerosol system), 8 inhalations four times per day for 14 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: MDI C (chlorofluorocarbon propellant), 4 inhalations four times per day for 14 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: MDI C (chlorofluorocarbon propellant), 8 inhalations four times per day for 14 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: MDI A (HFA-134a inhalation aerosol system)
Number of subjects: 16

Group type: COMPARATOR
Intervention: MDI C (chlorofluorocarbon propellant)
Number of subjects: 16
Study: 1584429

Group type: EXPERIMENTAL
Intervention: Selegiline monotherapy
Number of subjects: 0
Study: 6463426

Group type: EXPERIMENTAL
Intervention: Acetyl‐beta‐methylcholine (M)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Histamine phosphate (H)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Isotonic buffered saline (control)
Number of subjects: 9
Study: 31048645

Group type: COMPARATOR
Intervention: Postoperative intravenous antibiotics once on the day of surgery and oral antibiotics for 4 days (Control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: No postoperative antibiotics (Experimental group)
Number of subjects: 30
Study: 29507938

Group type: EXPERIMENTAL
Intervention: Daily antituberculosis therapy
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Part-daily antituberculosis therapy
Number of subjects: 331

Group type: COMPARATOR
Intervention: Intermittent antituberculosis therapy
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 331
Study: 27764725

Group type: EXPERIMENTAL
Intervention: H-BE (600-mg total anthocyanins)
Number of subjects: 23

Group type: COMPARATOR
Intervention: CON (no blackcurrant extract)
Number of subjects: 23
Study: 25241758

Group type: EXPERIMENTAL
Intervention: (-)-OSU6162
Number of subjects: 15
Study: 23137495

Group type: EXPERIMENTAL
Intervention: Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS)
Number of subjects: 501

Group type: COMPARATOR
Intervention: XIENCE everolimus-eluting metallic stent
Number of subjects: 501
Study: 20491843

Group type: EXPERIMENTAL
Intervention: DS with WBV (DS+)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: DS without WBV (DS-)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SS with WBV (SS+)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SS without WBV (SS-)
Number of subjects: 10
Study: 18025765

Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 248

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 248
Study: 15644017

Group type: EXPERIMENTAL
Intervention: GlideScope
Number of subjects: 20

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 20
Study: 11878655

Group type: COMPARATOR
Intervention: Rectal paracetamol (40-60 mg kg-1 single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rectal paracetamol (14-20 mg kg-1 repeat dosing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rectal paracetamol (10-20 mg kg-1 single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parenteral paracetamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paracetamol + NSAID
Number of subjects: 0

Group type: COMPARATOR
Intervention: NSAID
Number of subjects: 0
Study: 10342698

Group type: EXPERIMENTAL
Intervention: Impregnated bednets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Improved sexually-transmitted disease (STD) treatment services
Number of subjects: 0
Study: 7774469

Group type: EXPERIMENTAL
Intervention: PEG‐ELS (n = 124)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: PEG‐ELS + oral metoclopramide (n = 99)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate (n = 106)
Number of subjects: 329
Study: 2330929

Group type: EXPERIMENTAL
Intervention: Cold-recombinant bivalent A vaccine
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated vaccine
Number of subjects: 189
Study: 6768270

Group type: EXPERIMENTAL
Intervention: Semi-upright position at 45 degrees in bed or early ambulation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Patients kept in bed
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ambulatory patients
Number of subjects: 90
Study: 31838622

Group type: EXPERIMENTAL
Intervention: Magnesium and Ketamine (Mg + K)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketamine (K)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 60
Study: 30810700

Group type: EXPERIMENTAL
Intervention: Stress imaging
Number of subjects: 8518

Group type: EXPERIMENTAL
Intervention: Nonimaging exercise tolerance test (ETT)
Number of subjects: 8518

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography
Number of subjects: 8518
Study: 28151412

Group type: EXPERIMENTAL
Intervention: Extended hemodialysis hours (≥24 hours)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard hemodialysis hours (target 12‐15 hours, maximum 18 hours)
Number of subjects: 200
Study: 26652098

Group type: EXPERIMENTAL
Intervention: Toothbrush and toothpaste
Number of subjects: 30

Group type: COMPARATOR
Intervention: Chlorhexidine solution and swab
Number of subjects: 30
Study: 24299607

Group type: EXPERIMENTAL
Intervention: Xinfeng Capsule
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (imitation leflunomide)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (imitation Xinfeng Capsule)
Number of subjects: 100
Study: 21319908

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction intervention
Number of subjects: 697

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 697
Study: 19165109

Group type: EXPERIMENTAL
Intervention: SilvaSorb Gel
Number of subjects: 24

Group type: COMPARATOR
Intervention: Silvadene silver sulfadiazine cream
Number of subjects: 24
Study: 17262140

Group type: COMPARATOR
Intervention: G1: glazed (control)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: G2: diamond bur finishing
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: G3: G2 + silicon rubber tip polishing
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: G4: G3 + felt disc/diamond polishing paste
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: G5: G3 + felt disc impregnated with fine‐particle diamond paste
Number of subjects: 25
Study: 12954578

Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg/day
Number of subjects: 0
Study: 10859079

Group type: EXPERIMENTAL
Intervention: Colonic J-pouch
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (Straight coloanal anastomosis)
Number of subjects: 47
Study: 9337167

Group type: EXPERIMENTAL
Intervention: Preincisional or intraincisional infiltration with metronidazole (0.915 g metronidazole disodium phosphate injection in 100 mL 0.9% normal saline, injected 60-80 mL into subcutaneous tissue and muscle).
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control group received intravenous injection of metronidazole disodium phosphate and cephazolin postoperatively.
Number of subjects: 239
Study: 8441838

Group type: EXPERIMENTAL
Intervention: Dopamine IV at 2 micrograms/kg/min in 0.45% NaCl at 100 mL/h for 2 h during and after cardiac catheterization
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.45% NaCl IV at 100 mL/h (Group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dopamine IV at 2 micrograms/kg/min in 0.45% NaCl at 100 mL/h (Group 2)
Number of subjects: 30
Study: 3154147

Group type: EXPERIMENTAL
Intervention: 16-week treatment program for wife assault
Number of subjects: 50
Study: 30134136

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g administered intravenously)
Number of subjects: 3891

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3891
Study: 27516409

Group type: EXPERIMENTAL
Intervention: Physical practice
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Point-light model
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Video model
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 23796946

Group type: EXPERIMENTAL
Intervention: Fish oil (2.2 g/day LC-n3-FA)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 22541046

Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 20724426

Group type: EXPERIMENTAL
Intervention: Leukocyte filtration (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: In-vitro stimulated neutrophil responses
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Leukocyte filtration
Number of subjects: 40
Study: 19039554

Group type: EXPERIMENTAL
Intervention: Manual technique for analyzing dynamic antral scintigraphy (DAS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Automated technique (fast Fourier transform) for analyzing dynamic antral scintigraphy (DAS)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both manual and automated techniques
Number of subjects: 21
Study: 15001305

Group type: EXPERIMENTAL
Intervention: Home IV therapy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Hospital IV therapy
Number of subjects: 82
Study: 11336365

Group type: EXPERIMENTAL
Intervention: Hip arthroscopy (with or without debridement)
Number of subjects: 68